AbbVie - 3110-305-002: Pediatric Migraine

Watching your child struggle with migraines can feel helpless—but you’re not alone. The PERISCOPE Study is a clinical research study designed to evaluate a potential new treatment option for children and adolescents ages 6 to 17 who experience migraines.

PERISCOPE Pediatric Migraine Study

This study is helping researchers learn more about a treatment that is already approved for migraine relief in adults and is now being studied for younger patients. All study-related care is provided at no cost, and families may receive compensation for time and travel. No health insurance is required to participate.

Frequently Asked Questions

Who May Qualify?

You or your child may be eligible if they:

Are 6 to 17 years old
Have experienced migraines for at least 6 months
Have 1 to 14 migraine attacks per month

Participation includes study visits, evaluations, and access to the investigational product—all provided at no cost.

What is pediatric migraine?

Pediatric migraine is a neurological condition that causes recurring headaches in children and adolescents. These headaches may be accompanied by nausea, vomiting, sensitivity to light or sound, and can interfere with school and daily activities.

How common are migraines in children and teens?

Migraines affect millions of children worldwide and often begin during school-age years or adolescence. The frequency and severity can increase over time if not properly managed.

How are pediatric migraines typically treated?

Treatment may include lifestyle changes, avoiding triggers, and medications to relieve or prevent migraines. Clinical studies like the PERISCOPE Study help evaluate new treatment options specifically designed for children and adolescents.